tislelizumab + etoposide + pegaspargase

**tislelizumab + etoposide + pegaspargase** is a combination regimen comprising three agents: - **Tislelizumab**: a monoclonal antibody targeting the programmed death-1 (PD-1) receptor, acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. - **Etoposide**: a small molecule chemotherapeutic agent that inhibits DNA topoisomerase II, leading to DNA damage and apoptosis in proliferating cells. - **Pegaspargase**: a pegylated form of the enzyme L-asparaginase, which depletes circulating asparagine levels and inhibits protein synthesis in asparagine-dependent tumor cells, particularly effective in certain lymphoid malignancies. This combination is under investigation for the treatment of **relapsed/refractory extranodal NK/T-cell lymphoma**. The rationale is to combine immunotherapy (tislelizumab) with cytotoxic chemotherapy (etoposide) and targeted enzymatic therapy (pegaspargase) to overcome the poor prognosis associated with relapsed/refractory disease and improve remission rates. Early clinical studies suggest this approach is being evaluated for safety and effectiveness in this indication[3][6].